Investor Presentaiton

Strong Delivery from our R&D Engine Since R&D Day Opdivo Oncology - U.S. approval in Stage II adj. melanoma - Peri-adj. lung & 1L MIUC presented at ESMO - Met co-primary endpoints for SC nivolumab¹ Krazati² - 1L lung TPS ≥ 50% encouraging Ph2 data at ESMO Immunology LPA₁ antagonist - Breakthrough Therapy Designation granted in PPF CD19 NEXT Cell Therapy - Enrolling patients in Ph1 severe, refractory SLE trial - Achieved FDA clearance to initiate MS trial Hematology Reblozyl - U.S. approval in 1L MDS associated anemia with a broad label Other assets - Data to be presented on key assets at ASH 2023 ll Bristol Myers Squibb Q3 2023 Results 1. Subcutaneous nivolumab could provide U.S. approval in indications representing 65-75% of Opdivo business & benefit patients into the early 2030s 2. Subject to satisfaction of customary closing conditions; anticipated closing by 1H 2024 Not for Product Promotional Use 80

View entire presentation